References of "Petrossians, Patrick"
     in
Bookmark and Share    
Peer Reviewed
See detailLes hyperparathyroidies primaires: étiologies, diagnostic et traitement.
Janssens, L.; Verbeke, V.; Petrossians, Patrick ULg et al

in Revue Médicale de Liège (2000), 55(11), 977-985

L'hyperparathyroïdie primaire est une maladie trop souvent méconnue. Son incidence est estimée à 28/100.000, soit environ 2.800 nouveaux cas par an en Belgique. La fréquence de l'hyperparathyroïdie ... [more ▼]

L'hyperparathyroïdie primaire est une maladie trop souvent méconnue. Son incidence est estimée à 28/100.000, soit environ 2.800 nouveaux cas par an en Belgique. La fréquence de l'hyperparathyroïdie augmente avec l'âge. En effet, 50 % des cas sont rencontrés après l'âge de 70 ans et 3 à 4 % des femmes au-delà de 70 ans sont touchées par l'affection. Cette affection peut être sporadique ou survenir dans un cadre étiologique plus complexe tel que les polyendocrinopathies ou la neurofibromatose. L'attention vers ce diagnostic doit être attirée par une symptomatologie, souvent bâtarde, de fatigue (parfois isolée), de polyurie, de polydipsie, d'hypertension artérielle ou la présence de lithiases rénales. Lorsque le diagnostic d'hyperparathyroïdie est renteu, il convient de localiser la ou les glande(s) pathologique(s) et de définir le contexte étiologique qui pourra déterminer le choix thérapeutique le plus approprié. Une étude biologique simple sera réalisée devant toute suspicion d'hyperparathyroïdie. Dans certains cas, le diagnostic sera aidé par la réalisation d'un test de surcharge calcique qui peut permettre de confirmer l'hyperparathyroïdie et d'apprécier son degré d'autonomisation. [less ▲]

Detailed reference viewed: 68 (3 ULg)
Full Text
Peer Reviewed
See detailMalignant prolactinoma discovered by D2 receptor imaging.
Petrossians, Patrick ULg; de Herder, W.; Kwekkeboom, D. et al

in Journal of Clinical Endocrinology and Metabolism (2000), 85(1), 398-401

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailCabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst, Johan; Abs, Roger; Maiter, Dominique et al

in Journal of Clinical Endocrinology and Metabolism (1999), 84(7), 2518-22

Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number ... [more ▼]

Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the effect on clinical symptoms, tumor shrinkage, and visual field abnormalities. We also evaluated the effects of cabergoline in a large subgroup of patients with bromocriptine intolerance or -resistance. We retrospectively reviewed the files of 455 patients (102 males and 353 females) with pathological hyperprolactinemia treated with cabergoline in 9 Belgian centers. Among these patients, 41% had a microadenoma; 42%, a macroadenoma; 16%, idiopathic hyperprolactinemia; and 1%, an empty sella. The median pretreatment serum PRL level was 124 microg/L (range, 16-26,250 microg/L). A subgroup of 292 patients had previously been treated with bromocriptine, of which 140 showed bromocriptine intolerance and 58 showed bromocriptine resistance. Treatment with cabergoline normalized serum PRL levels in 86% of all patients: in 92% of 244 patients with idiopathic hyperprolactinemia or a microprolactinoma and in 77% of 181 macroadenomas. Pretreatment visual field abnormalities normalized in 70% of patients, and tumor shrinkage was seen in 67% of cases. Side effects were noted in 13% of patients, but only 3.9% discontinued therapy because of side effects. The median dose of cabergoline at the start of therapy was 1.0 mg/week but could be reduced to 0.5 mg/week once control was achieved. Patients with a macroprolactinoma needed a higher median cabergoline dose, compared with those with idiopathic hyperprolactinemia or a microprolactinoma: 1.0 mg/week vs. 0.5 mg/week, although a large overlap existed between these groups. Twenty-seven women treated with cabergoline became pregnant, and 25 delivered a healthy child. One patient had an intended abortion and another a miscarriage. In the patients with bromocriptine intolerance, normalization of PRL was reached in 84% of cases, whereas in the bromocriptine-resistant patients, PRL could be normalized in 70%. We confirmed, in a large-scale retrospective study, the high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia, leaving few patients with unacceptable side effects or inadequate clinical response. Patients with idiopathic hyperprolactinemia or a microprolactinoma, on average, needed only half the dose of cabergoline as those with macroprolactinomas and have a higher chance of obtaining PRL normalization. Cabergoline also normalized PRL in the majority of patients with known bromocriptine intolerance or -resistance. Once PRL secretion was adequately controlled, the dose of cabergoline could often be significantly decreased, which further reduced costs of therapy. [less ▲]

Detailed reference viewed: 58 (2 ULg)
Full Text
Peer Reviewed
See detailFamilial Acromegaly: Case Report and Review of the Literature
Verloes, Alain ULg; Stevenaert, Achille ULg; Teh, B. T. et al

in Pituitary (1999), 1(3-4), 273-277

Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been ... [more ▼]

Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been shown to develop acromegaly. In 4 patients, clinical follow-up, and biological screening allowed to confidently exclude MEN1. Absence of mutation in the MEN1 gene after direct DNA analysis in 2 pedigrees reinforces the conviction that the families do not have MEN1. In families 1 and 2, diagnosis was made at a very early age and voluminous adenomas with suprasellar expansion were already present at the time of diagnosis. We review the 20 previous reports of familial acromegaly, some of them questionable. Our 3 families, combined with some other published pedigrees, allow the delineation of a familial form of acromegaly, distinct from MEN1. Dominant inheritance with reduced, age-dependant penetrance is the most parsimonious model to explain the recurrences. Gs protein pathway could be the site of action of the gene responsible of familial acromegaly, but no data have been published to sustain or reject this hypothesis. [less ▲]

Detailed reference viewed: 23 (1 ULg)
See detailCabergoline in the treatment of Hyoerprolactinemia : A study in 455 patients
Verhelst, J.; Abs, R.; Maiter, D. et al

in 9th Meeting and workshop of the European Neuroendocrine Association - Abstract book (1999)

Detailed reference viewed: 3 (0 ULg)
See detailFamilial Acromegaly : Case report and review of the litterature
Beckers, Albert ULg; Stevenaert, Achille ULg; Teh, B. T. et al

in The 6th International Pituitary Congress - Abstract book (1999)

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailAn unusual pituitary pathology
Petrossians, Patrick ULg; Delvenne, Philippe ULg; Flandroy, P. et al

in Journal of Clinical Endocrinology and Metabolism (1998), 83(10), 3454-3458

Detailed reference viewed: 17 (2 ULg)
See detailInsuffisance hypophysaire et amaurose subaiguës causées par une pseudotumeur inflammatoire extensive du sinus sphénoïde
Hansen, Isabelle ULg; Petrossians, Patrick ULg; Flandroy, Pierre et al

in XVI Congrès de la Société Française d'Endocrinologie - Abstract book (1998)

Detailed reference viewed: 41 (0 ULg)
Full Text
See detailAn epidemiological survey of 783 patients who underwent pituitary surgery in a single Centre over a 25-year periods
Beckers, Albert ULg; Petrossians, Patrick ULg; Stevenaert, Achille ULg

in 24th International Symposium on GH and growth factors in Endocrinology and Metabolism - Abstract book (1997)

Detailed reference viewed: 5 (0 ULg)
See detailGrowth hormone secretion during pregnancy in an acromegalic woman
Petrossians, Patrick ULg; Chanson, P.; Schaison, G. et al

in 10th international Congress of Endocrinology - Abstract book (1996)

Detailed reference viewed: 6 (0 ULg)
See detailSerum GH response to the administration of TRh
Petrossians, Patrick ULg; Abs, R.; Beckers, Albert ULg

in Acta Clinica Belgica (1993), 48

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailTreatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
Beckers, Albert ULg; Petrossians, Patrick ULg; Abs, R. et al

in Journal of Clinical Endocrinology and Metabolism (1992), 75(1), 275-80

Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They ... [more ▼]

Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They were divided into two groups: group I consisted of 22 patients who received Parlodel LAR before transsphenoidal adenomectomy; group II was composed of 7 patients with earlier neurosurgery and of 2 patients from group I not cured by transsphenoidal adenomectomy. Duration of therapy varied from 1-12 months, and a total of 104 injections was given. At nadir day, serum PRL levels were situated between less than 1% and 43% of pretreatment values. At day 28 after the first injection, serum PRL levels varied between less than 1% to 139% of initial values. No difference could be detected between the two groups regarding the percent of PRL inhibition. Long-term treatment with Parlodel-LAR resulted in a sustained inhibition of PRL secretion, except for 1 case. Resumption of menstrual cycles occurred in 4 out of 15 women and correction of hypogonadism in 4 out of 14 men. Amelioration of disturbed visual fields was recorded in 3 out of 8 patients. Diminution of the adenoma volume was radiologically documented in 14 out of 22 cases. Only few and mild side effects were recorded. One patient with partial adrenal deficiency suffered from a syncope, but this was prevented by hydrocortisone supplementation during the subsequent Parlodel-LAR administration. In conclusion, Parlodel-LAR proved effective in the treatment of macroprolactinomas, achieving rapid inhibition of PRL secretion, and in some patients amelioration of hypopituitarism, reduction in tumor size, and improvement in visual fields, and caused no serious side effects. It is a valuable preparation to surgery and can also be used in long-term medical therapy. [less ▲]

Detailed reference viewed: 5 (0 ULg)
See detailTratamiento farmacologico de la hiperprolactinemia
Petrossians, Patrick ULg; Stevenaert, Achille ULg; Beckers, Albert ULg

in Hiperprolactinemias : Avances en el Diagnostico y tratamiento de las hiperprolactinemias (1989)

Detailed reference viewed: 15 (0 ULg)
See detailDie medikamentöse behandlung von prolaktinomen mit Cabergolin
Petrossians, Patrick ULg; Stevenaert, Achille ULg; Beckers, Albert ULg

in Aktuelle Diagnostik und therapie bei Störungen der Prolaktinsekretin (1989)

Detailed reference viewed: 9 (0 ULg)